Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars
Eylea Biosimilar Option Exercised
Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.
